세계의 결핵(TB) 진단 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Tuberculosis (TB) Diagnostics was estimated to be worth US$ 3070 million in 2024 and is forecast to a readjusted size of US$ 4149 million by 2031 with a CAGR of 4.5% during the forecast period 2025-2031.

Tuberculosis (TB) is an infectious disease usually caused by the bacterium Mycobacterium tuberculosis (MTB). Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections do not have symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those infected. The classic symptoms of active TB are a chronic cough with blood-containing sputum, fever, night sweats, and weight loss. The historical term "consumption" came about due to the weight loss. Infection of other organs can cause a wide range of symptoms.

The global TB diagnostics market is being propelled by the urgent need to improve disease detection and control in response to the persistent burden of tuberculosis, particularly in high-prevalence regions. Efforts to reach WHO's End TB goals have elevated funding for TB programs, driving the rollout of advanced diagnostic tools like molecular assays , X-ray based screening solutions with AI assistance, and point-of-care tests. Furthermore, increasing integration of TB screening within broader healthcare initiatives-such as universal healthcare coverage and integrated respiratory disease programs-has expanded testing capacity. The push to screen high-risk populations, including people living with HIV, healthcare workers, migrants, and prison inmates, has also increased demand for rapid, accurate, and decentralized diagnostic methods capable of delivering same-day results and guiding treatment decisions.

Despite significant advancements in TB diagnostics, substantial barriers continue to hinder market expansion. One major challenge is inconsistent access to cutting-edge diagnostic tools in low- and middle-income countries, where infrastructure remains limited and centralized laboratory systems struggle to support widespread deployment. Additionally, the cost of advanced molecular and imaging technologies remains a deterrent, particularly when factoring in expenses for equipment maintenance, consumables, and the specialized training required for healthcare personnel. The regulatory and logistical complexities involved in distributing diagnostic platforms-especially in remote rural areas-also slow down adoption. Finally, the co-existence of disparate diagnostic algorithms across countries, combined with variable healthcare funding and weak supply chain systems, continues to limit consistent implementation of guideline-compliant testing and undermines efforts to significantly reduce TB incidence.

Global Tuberculosis (TB) Diagnostics key players include Danaher, Roche, Thermo Fisher Scientific, BD, Abbott, etc. Global top five manufacturers hold a share about 33%. APAC is the largest market, with a share over 40%, followed by Americas and Europe, both have a share about 40 percent.

This report aims to provide a comprehensive presentation of the global market for Tuberculosis (TB) Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Tuberculosis (TB) Diagnostics by region & country, by Type, and by Application.

The Tuberculosis (TB) Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tuberculosis (TB) Diagnostics.

Market Segmentation

By Company

• Danaher
• Roche
• Thermo Fisher Scientific
• BD
• Abbott
• Hologic
• Qiagen
• BioMerieux
• Hain Lifescience
• Oxford Immunotec

Segment by Type

• Culture-Based Diagnostics
• Sputum Smear Microscopy
• Rapid Molecular Diagnostics
• Others

Segment by Application

• Diagnostic Laboratories
• Hospitals

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Tuberculosis (TB) Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Tuberculosis (TB) Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Tuberculosis (TB) Diagnostics in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Tuberculosis (TB) Diagnostics Product Introduction
• 1.2 Global Tuberculosis (TB) Diagnostics Market Size Forecast (2020-2031)
• 1.3 Tuberculosis (TB) Diagnostics Market Trends & Drivers
  • 1.3.1 Tuberculosis (TB) Diagnostics Industry Trends
  • 1.3.2 Tuberculosis (TB) Diagnostics Market Drivers & Opportunity
  • 1.3.3 Tuberculosis (TB) Diagnostics Market Challenges
  • 1.3.4 Tuberculosis (TB) Diagnostics Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Tuberculosis (TB) Diagnostics Players Revenue Ranking (2024)
• 2.2 Global Tuberculosis (TB) Diagnostics Revenue by Company (2020-2025)
• 2.3 Key Companies Tuberculosis (TB) Diagnostics Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Tuberculosis (TB) Diagnostics Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Tuberculosis (TB) Diagnostics
• 2.6 Tuberculosis (TB) Diagnostics Market Competitive Analysis
  • 2.6.1 Tuberculosis (TB) Diagnostics Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Tuberculosis (TB) Diagnostics Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tuberculosis (TB) Diagnostics as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Culture-Based Diagnostics
  • 3.1.2 Sputum Smear Microscopy
  • 3.1.3 Rapid Molecular Diagnostics
  • 3.1.4 Others
• 3.2 Global Tuberculosis (TB) Diagnostics Sales Value by Type
  • 3.2.1 Global Tuberculosis (TB) Diagnostics Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Tuberculosis (TB) Diagnostics Sales Value, by Type (2020-2031)
  • 3.2.3 Global Tuberculosis (TB) Diagnostics Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Diagnostic Laboratories
  • 4.1.2 Hospitals
• 4.2 Global Tuberculosis (TB) Diagnostics Sales Value by Application
  • 4.2.1 Global Tuberculosis (TB) Diagnostics Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Tuberculosis (TB) Diagnostics Sales Value, by Application (2020-2031)
  • 4.2.3 Global Tuberculosis (TB) Diagnostics Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Tuberculosis (TB) Diagnostics Sales Value by Region
  • 5.1.1 Global Tuberculosis (TB) Diagnostics Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Tuberculosis (TB) Diagnostics Sales Value by Region (2020-2025)
  • 5.1.3 Global Tuberculosis (TB) Diagnostics Sales Value by Region (2026-2031)
  • 5.1.4 Global Tuberculosis (TB) Diagnostics Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
  • 5.2.2 North America Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
  • 5.3.2 Europe Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Tuberculosis (TB) Diagnostics Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
  • 5.5.2 South America Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Tuberculosis (TB) Diagnostics Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Tuberculosis (TB) Diagnostics Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
  • 6.3.2 United States Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
  • 6.4.2 Europe Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
  • 6.5.2 China Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
  • 6.6.2 Japan Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
  • 6.7.2 South Korea Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Tuberculosis (TB) Diagnostics Sales Value, 2020-2031
  • 6.9.2 India Tuberculosis (TB) Diagnostics Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Tuberculosis (TB) Diagnostics Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Danaher
  • 7.1.1 Danaher Profile
  • 7.1.2 Danaher Main Business
  • 7.1.3 Danaher Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • 7.1.4 Danaher Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
  • 7.1.5 Danaher Recent Developments
• 7.2 Roche
  • 7.2.1 Roche Profile
  • 7.2.2 Roche Main Business
  • 7.2.3 Roche Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • 7.2.4 Roche Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
  • 7.2.5 Roche Recent Developments
• 7.3 Thermo Fisher Scientific
  • 7.3.1 Thermo Fisher Scientific Profile
  • 7.3.2 Thermo Fisher Scientific Main Business
  • 7.3.3 Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • 7.3.4 Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
  • 7.3.5 Thermo Fisher Scientific Recent Developments
• 7.4 BD
  • 7.4.1 BD Profile
  • 7.4.2 BD Main Business
  • 7.4.3 BD Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • 7.4.4 BD Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
  • 7.4.5 BD Recent Developments
• 7.5 Abbott
  • 7.5.1 Abbott Profile
  • 7.5.2 Abbott Main Business
  • 7.5.3 Abbott Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • 7.5.4 Abbott Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
  • 7.5.5 Abbott Recent Developments
• 7.6 Hologic
  • 7.6.1 Hologic Profile
  • 7.6.2 Hologic Main Business
  • 7.6.3 Hologic Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • 7.6.4 Hologic Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
  • 7.6.5 Hologic Recent Developments
• 7.7 Qiagen
  • 7.7.1 Qiagen Profile
  • 7.7.2 Qiagen Main Business
  • 7.7.3 Qiagen Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • 7.7.4 Qiagen Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
  • 7.7.5 Qiagen Recent Developments
• 7.8 BioMerieux
  • 7.8.1 BioMerieux Profile
  • 7.8.2 BioMerieux Main Business
  • 7.8.3 BioMerieux Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • 7.8.4 BioMerieux Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
  • 7.8.5 BioMerieux Recent Developments
• 7.9 Hain Lifescience
  • 7.9.1 Hain Lifescience Profile
  • 7.9.2 Hain Lifescience Main Business
  • 7.9.3 Hain Lifescience Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • 7.9.4 Hain Lifescience Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
  • 7.9.5 Hain Lifescience Recent Developments
• 7.10 Oxford Immunotec
  • 7.10.1 Oxford Immunotec Profile
  • 7.10.2 Oxford Immunotec Main Business
  • 7.10.3 Oxford Immunotec Tuberculosis (TB) Diagnostics Products, Services and Solutions
  • 7.10.4 Oxford Immunotec Tuberculosis (TB) Diagnostics Revenue (US$ Million) & (2020-2025)
  • 7.10.5 Oxford Immunotec Recent Developments

8 Industry Chain Analysis

• 8.1 Tuberculosis (TB) Diagnostics Industrial Chain
• 8.2 Tuberculosis (TB) Diagnostics Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Tuberculosis (TB) Diagnostics Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Tuberculosis (TB) Diagnostics Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer